NOVARTIS INDIA LTD. - 500672 - Shareholding for the Period Ended March 31, 2020
Novartis India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here05-05-2020
05-05-2020
NOVARTIS INDIA LTD. - 500672 - Compliance Certificate Of Novartis India Limited Under Regulation 7(3) Read With Regulation 7(2) Of The SEBI Listing Obligations And Disclosure Requirements) Regulations, 2015 For Half Year Ended On March 31, 2020.
As per the requirement of Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facility during the period October 1, 2019 to March 31, 2020 (both days inclusive) are maintained by the Company's Registrar & Transfer Agent, viz. Link Intime India Private Limited, which is registered as Registrar & Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number : INR000004058.05-05-2020
NOVARTIS INDIA LTD. - 500672 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Dear Sir/ Madam, In reference to the above captioned subject, the certificate dated April 29, 2020 issued by the Registrar and Transfer Agent of the Company i.e. Link Intime India Private Limited, in terms of the provisions of the said Regulations, for the quarter ended on March 31, 2020 is enclosed herewith for your records as Annexure 1. This is for your information and record.05-05-2020
Coronavirus: Novartis, US regulators agree on hydroxycloroquine trial against COVID-19
Hydroxycloroquine (HCQ) has received U.S. Food and Drug Administration (FDA) emergency use authorization for coronavirus disease, but so far there is no scientific proof it helps those afflicted20-04-2020
Novartis scraps deal with Aurobindo Pharma after failing to get FTC nod
Novartis AG said on Thursday it had scrapped the sale of its US dermatology and generic pill assets to India's Aurobindo Pharma Ltd after failing to g02-04-2020
NOVARTIS INDIA LTD. - 500672 - Announcement under Regulation 30 (LODR)-Retirement
Kindly note that the term of Dr. Rajendra Nath Mehrotra [DIN - 00172639] as an Independent Director of the Company would end on March 31, 2020. Dr. Mehrotra was re-appointed as an Independent Director of the Company, for a second term, vide special resolution passed by the shareholders of the Company through postal ballot, for a period of one year commencing from April 1, 2019 upto March 31, 2020. Accordingly, his tenure will end today i.e. March 31, 2020. The Board of Directors of the Company have placed on record their appreciation for respectable contributions made by Dr. Mehrotra during his tenure as an Independent Director of the Company. The Nomination and Remuneration Committee of the Board, is in the process of identifying a suitable successor to Dr. Mehrotra. This is for your information.31-03-2020
NOVARTIS INDIA LTD. - 500672 - Closure of Trading Window
Pursuant to the Company''s Code of Conduct to regulate, monitor and report share trading by Insiders ["the Code"], the trading window for dealing in securities of the Company shall remain closed from Wednesday, April 1, 2020. The Trading Window shall open 48 (forty eight) hours after the Financial results are made public. The same is being duly communicated to all the Designated Persons under the Code which is available on the Company''s website i.e. www.novartis.in. This is for your information.31-03-2020
Novartis CEO says Malaria drug biggest hope against coronavirus: Newspaper
Malaria, lupus and arthritis drug hydroxychloroquine is under clinical trials, says Novartis.29-03-2020
Coronavirus pandemic | Novartis works with life sciences companies to fight COVID-19
Fifteen companies have agreed to share their libraries of compounds that already have some degree of safety and activity data. Successful hits would move rapidly into in vivo trials in as little as two months, Novartis said in a statement on March 26.26-03-2020
Novartis to donate doses of malaria drug to fight against coronavirus
In Washington, U.S. President Donald Trump said during a news conference on Friday he is optimistic about the malaria treatment's use against COVID-1921-03-2020